Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT04670445
Official study title

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

Study summary

The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer. The intervention is an educational video and question prompt list (QPL) to promote communication between patients, caregivers, and the oncology team about the risks and benefits of immunotherapy.

Ask AI to explain this study
Start here

Key things to know

Main goalHealth Services Research

This describes the study’s primary purpose.

What is being studiedEducational Video and QPL List and Usual Care

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Small cell lung cancer (SCLC) · Mesothelioma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 25, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Massachusetts General Hospital

Study sponsor

01
Study overview

What this study is about

Purpose
Health Services Research
Study type
Interventional
Phase
Not applicable
Sponsor
Massachusetts General Hospital
Interventions being studied
Other: Educational Video and QPL List; Other: Usual Care
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→Small cell lung cancer (SCLC)→Mesothelioma→
Disease setting
Early-stage or resectable→Locally advanced→Metastatic or stage IV→
Treatment approach
Immunotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • All participants (Patients and Caregivers)-Table 1
  • Age 18 or older
  • Ability to read and respond in English
  • Patient Inclusion Criteria (in addition to Table 1)
  • Receiving care in the MGH Cancer Center
  • Diagnosis of advanced (stage IV) melanoma or advanced, incurable lung cancer, including stage IV non-small cell lung cancer (NSCLC), unresectable stage III NSCLC, extensive-stage small cell lung cancer.
  • Plan to initiate immunotherapy with an ICI (pembrolizumab, nivolumab, ipilimumab, atezolizumab or combination), per clinician documentation in the electronic health record or study staff communication with clinician
  • Caregiver Inclusion Criteria (in addition to Table 1)
  • Identified as "a supportive person involved in their cancer care" by a patient enrolled in the study
Reasons someone may not be able to joinExclusion criteria
  • Major psychiatric condition or comorbid illness that prohibits participation in the study
  • Cognitive impairment that prohibits provision of informed consent or participation in the study
  • Pregnant women
  • Prisoners

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Massachusetts General HospitalBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 25, 2026. Always confirm current availability with the study team.

View original record ↗